Revolution Medicines
Updated: April 18, 2026
Mark A. Goldsmith - Founding President & CEO
Country: USA | Funding: $4.3B (+)
Founded: 2015
Website: https://www.revmed.com
Revolution Medicines develops novel treatments for cancers associated with RAS activation (which accounts for 30 percent of all new human cancer diagnoses). The company is building a portfolio of RAS(ON) inhibitors using its tricomplex inhibitor platform, which provides unprecedented access to the active form of oncogenic RAS. Revolution Medicines is building a comprehensive pipeline of targeted therapies for the discovery, development, and delivery of new therapeutic options for PDAC, NSCLC, and solid tumors. The pipeline is designed to allow the evaluation of compounds as monotherapies and in combination with existing standard-of-care therapies and/or other compounds within our portfolio.
Founded: 2015
Website: https://www.revmed.com
Revolution Medicines develops novel treatments for cancers associated with RAS activation (which accounts for 30 percent of all new human cancer diagnoses). The company is building a portfolio of RAS(ON) inhibitors using its tricomplex inhibitor platform, which provides unprecedented access to the active form of oncogenic RAS. Revolution Medicines is building a comprehensive pipeline of targeted therapies for the discovery, development, and delivery of new therapeutic options for PDAC, NSCLC, and solid tumors. The pipeline is designed to allow the evaluation of compounds as monotherapies and in combination with existing standard-of-care therapies and/or other compounds within our portfolio.
